Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xywav in Idiopathic Hypersomnia
NCT03533114Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in idiopathic hypersomnia (IH) comparing JZP-258 with Placebo (2 arms). Primary endpoint: Epworth Sleepiness Scale at 2 weeks. Started Nov 2018; status: completed.
02
Drugs
sodium oxybate + calcium oxybate + potassium oxybate + magnesium oxybate
03
Conditions
idiopathic hypersomnia (IH)
Beyond the preview
Go deeper on NCT03533114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03533114.